Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Net Income towards Common Stockholders (2016 - 2025)

Palisade Bio (PALI) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 17.75% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.3 million, a 20.94% increase, with the full-year FY2024 number at -$14.9 million, down 13.65% from a year prior.
  • Net Income towards Common Stockholders was -$2.9 million for Q3 2025 at Palisade Bio, down from -$2.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $5.1 million in Q3 2021 to a low of -$31.7 million in Q2 2021.
  • A 5-year average of -$4.4 million and a median of -$3.4 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest YoY gain for Net Income towards Common Stockholders was 377.75% in 2021; the steepest drop was 1615.07% in 2021.
  • Palisade Bio's Net Income towards Common Stockholders stood at $5.1 million in 2021, then plummeted by 175.23% to -$3.9 million in 2022, then increased by 18.0% to -$3.2 million in 2023, then decreased by 7.19% to -$3.4 million in 2024, then grew by 15.27% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Net Income towards Common Stockholders are -$2.9 million (Q3 2025), -$2.8 million (Q2 2025), and -$2.2 million (Q1 2025).